MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
ProPhase Labs Net Income 2011-2026 | PRPH
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income ProPhase Labs
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.5 M | 6.27 M | -2.12 M | -3.15 M | -1.74 M | 41.8 M | -2.87 M | -3.6 M | -7.83 M | 405 K | -1.09 M | -2.71 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.8 M | -7.83 M | 3.49 M |
Quarterly Net Income ProPhase Labs
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.84 M | -4.47 M | 3.97 M | - | -6.59 M | -6.15 M | -6.26 M | - | -5.14 M | -3.44 M | 550 K | - | 968 K | 7.45 M | 12.5 M | - | -3.98 M | -1.4 M | 1.06 M | - | -408 K | 70 K | -809 K | - | -428 K | -1.24 M | -1.01 M | - | -1.06 M | -259 K | 43 K | - | -777 K | -2.3 M | 43.9 M | - | 167 K | -1.13 M | -1.34 M | -1.26 M | 602 K | -1.57 M | -1.38 M | -676 K | -3.22 M | -3.14 M | -804 K | 597 K | 1.24 M | -1.72 M | 290 K | 453 K | 1.07 M | -1.93 M | -688 K | -1.83 M | 1.11 M | -976 K | -1.01 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 43.9 M | -6.84 M | 15.8 K |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Drug manufacturers industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-14.3 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-14.5 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-26.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-74.8 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
-1.04 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
35.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-2.45 B | - | - | $ 28.9 M |  Irlanda |
 |
DURECT Corporation
DRRX
|
-27.6 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
-20.1 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-48.8 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-7.79 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.9 M | $ 3.12 | 0.97 % | $ 43.9 M | USA |
 |
Cronos Group
CRON
|
-73.1 M | $ 2.57 | -0.39 % | $ 1.35 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-510 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-115 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
-592 M | $ 5.72 | 2.14 % | $ 2.09 B | Canada |
 |
Harrow Health
HROW
|
-5.14 M | $ 37.1 | 3.26 % | $ 1.36 B | USA |
 |
Aurora Cannabis
ACB
|
-695 M | $ 3.48 | 1.46 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-598 M | $ 1.08 | 2.86 % | $ 116 M | Canada |
 |
OrganiGram Holdings
OGI
|
-131 M | $ 1.42 | 1.43 % | $ 402 M | Canada |
 |
Jupiter Wellness
JUPW
|
-68.2 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-232 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-90.4 M | - | - | $ 193 M | Canada |
 |
Evolus
EOLS
|
-51.6 M | $ 4.33 | 1.41 % | $ 279 M | USA |
 |
Emergent BioSolutions
EBS
|
-760 M | $ 8.24 | 3.52 % | $ 422 M | USA |
 |
Sundial Growers
SNDL
|
-230 M | $ 1.37 | -3.52 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
861 K | $ 2.38 | - | $ 313 M | USA |
 |
Pacira BioSciences
PCRX
|
-99.6 M | $ 24.06 | 1.13 % | $ 1.11 B | USA |
 |
PetIQ
PETQ
|
2.13 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-57.4 M | $ 7.38 | 1.23 % | $ 291 M | USA |
 |
Assertio Holdings
ASRT
|
-30.4 M | $ 18.02 | - | $ 115 M | USA |
 |
Radius Health
RDUS
|
-70.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-13.3 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-35.5 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-8.61 M | $ 1.01 | 1.0 % | $ 50.4 M | USA |
 |
PLx Pharma
PLXP
|
-46.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-174 M | $ 8.39 | 4.61 % | $ 734 M | USA |
 |
Tilray
TLRY
|
-1.45 B | $ 6.72 | 2.28 % | $ 4.15 B | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.46 M | $ 2.35 | 3.07 % | $ 2.92 M | USA |
 |
Veru
VERU
|
-37.8 M | $ 2.38 | - | $ 321 M | USA |
 |
Viatris
VTRS
|
54.7 M | $ 13.83 | 2.67 % | $ 16.6 B | USA |
 |
cbdMD
YCBD
|
-153 K | $ 0.75 | 9.54 % | $ 3.23 M | USA |
 |
Zomedica Corp.
ZOM
|
-81.9 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-5.31 M | $ 0.94 | 3.31 % | $ 33.8 M | USA |
 |
Tricida
TCDA
|
-177 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.19 M | $ 0.65 | 0.6 % | $ 2.79 M |  China |
 |
TherapeuticsMD
TXMD
|
-569 K | $ 2.05 | -0.97 % | $ 23.7 M | USA |